ARWR Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Company profile
Ticker
ARWR
Exchange
Website
CEO
Christopher Anzalone
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ARROWHEAD RESEARCH CORP, INTERACTIVE GROUP INC, INTERACTIVE INC
SEC CIK
Corporate docs
IRS number
460408024
ARWR stock data
()
News
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
3 Jun 21
Arrowhead Receives $10M Option Exercise Fee From Janssen
18 May 21
ARWR: Catalyst-Rich Summer Upcoming…
6 May 21
Arrowhead Pharmaceuticals Q2 EPS $(0.26) Misses $(0.13) Estimate, Sales $32.81M Miss $37.70M Estimate
4 May 21
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
4 May 21
Press releases
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
3 Jun 21
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
2 Jun 21
Arrowhead Earns $10 Million Option Exercise Fee
18 May 21
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
12 May 21
Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results
4 May 21
Investment data
Securities sold
Number of investors
Calendar
4 May 21
13 Jun 21
30 Sep 21
Financial summary
Quarter (USD) |
Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Sep 20 | Sep 19 | Sep 18 | Sep 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 372.38M | 372.38M | 372.38M | 372.38M | 372.38M | 372.38M |
| Cash burn (monthly) | (positive/no burn) | (positive/no burn) | 9.41M | 9.86M | (positive/no burn) | (positive/no burn) |
| Cash used (since last report) | n/a | n/a | 22.88M | 23.98M | n/a | n/a |
| Cash remaining | n/a | n/a | 349.5M | 348.4M | n/a | n/a |
| Runway (months of cash) | n/a | n/a | 37.1 | 35.3 | n/a | n/a |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 22 Feb 21 | Given Douglas B | Common Stock | Sell | Dispose S | Yes | No | 88.73 | 1,125 | 99.82K | 13,875 |
| 8 Feb 21 | Patrick O'Brien | Common Stock | Sell | Dispose S | No | No | 89.66 | 5,436 | 487.39K | 293,375 |
| 8 Feb 21 | Patrick O'Brien | Common Stock | Sell | Dispose S | No | No | 88.88 | 45,348 | 4.03M | 298,811 |
| 8 Feb 21 | Patrick O'Brien | Common Stock | Sell | Dispose S | No | No | 88.08 | 31,255 | 2.75M | 344,159 |
| 8 Feb 21 | Patrick O'Brien | Common Stock | Sell | Dispose S | No | No | 86.72 | 7,961 | 690.38K | 375,414 |
| 8 Feb 21 | Patrick O'Brien | Common Stock | Option exercise | Aquire M | No | No | 5.22 | 90,000 | 469.8K | 383,375 |
| 8 Feb 21 | Patrick O'Brien | Stock Option Common Stock | Option exercise | Dispose M | No | No | 5.22 | 90,000 | 469.8K | 60,000 |
| 15 Jan 21 | Given Douglas B | Common Stock | Sell | Dispose S | Yes | No | 83.28 | 3,000 | 249.84K | 12,500 |
| 14 Jan 21 | James C Hamilton | Common Stock | Sell | Dispose S | No | No | 81.82 | 3,814 | 312.06K | 126,250 |
| 14 Jan 21 | James C Hamilton | Common Stock | Sell | Dispose S | No | No | 80.97 | 6,186 | 500.88K | 130,064 |
Institutional ownership Q1 2021
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
65.1% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 283 |
| Opened positions | 30 |
| Closed positions | 58 |
| Increased positions | 82 |
| Reduced positions | 123 |
13F shares |
Current |
|---|---|
| Total value | 5.24B |
| Total shares | 67.72M |
| Total puts | 372.71K |
| Total calls | 798.1K |
| Total put/call ratio | 0.5 |
Largest owners |
Shares | Value |
|---|---|---|
| BLK Blackrock | 12.9M | $855.48M |
| Vanguard | 9.6M | $636.65M |
| STT State Street | 3.73M | $247.61M |
| IVZ Invesco | 3.39M | $224.85M |
| Johnson & Johnson Innovation - JJDC | 3.26M | $216.23M |
| JPM JPMorgan Chase & Co. | 2.57M | $170.61M |
| Geode Capital Management | 1.76M | $116.47M |
| NTRS Northern Trust | 1.55M | $102.52M |
| CS Credit Suisse | 1.49M | $98.78M |
| FMR | 1.31M | $87M |
Financial report summary
?Competition
Sarepta Therapeutics • Biocryst Pharmaceuticals • Alnylam Pharmaceuticals • Altimmune • Dicerna Pharmaceuticals • Silence Therapeutics • Arcturus Therapeutics • Viridian Therapeutics • Codiak Biosciences • Akcea TherapeuticsManagement Discussion
- The increase in revenue for the three and six months ended March 31, 2021 compared to the three and six months ended March 31, 2020 was driven by the revenue recognized for the Takeda collaboration. The increase in net losses during the three and six months ended March 31, 2021 compared to the three and six months ended March 31, 2020 was driven by an increase in research and development expenses as our pipeline of clinical candidates has continued to increase and progress through clinical trial phases, partially offset by an increase in revenue from the Takeda License Agreement.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
canceled, convertible, dystrophy, facioscapulohumeral, Food, forfeited, grow, ii, individual, manner, maximum, muscular, tendered, track, unrealized, unrestricted, withheld, withholding
Removed:
advance, case, coupled, equal, funding, offering, secure, settle, source, superseded
Financial reports
10-Q
2021 Q2
Quarterly report
4 May 21
10-Q
2021 Q1
Quarterly report
4 Feb 21
10-K
2020 FY
Annual report
23 Nov 20
10-Q
2020 Q3
Quarterly report
5 Aug 20
10-Q
2020 Q2
Quarterly report
7 May 20
10-Q
2020 Q1
Quarterly report
5 Feb 20
10-K
2019 FY
Annual report
25 Nov 19
10-Q
2019 Q3
Quarterly report
5 Aug 19
10-Q
2019 Q2
Quarterly report
8 May 19
10-Q
2019 Q1
Quarterly report
7 Feb 19
Current reports
8-K
Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results
4 May 21
8-K
Departure of Directors or Certain Officers
24 Mar 21
8-K
Arrowhead Pharmaceuticals Reports Fiscal 2021 First Quarter Results
4 Feb 21
8-K
Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results
23 Nov 20
8-K
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
9 Oct 20
8-K
Departure of Directors or Certain Officers
8 Sep 20
8-K
Arrowhead Pharmaceuticals Reports Fiscal 2020 Third Quarter Results
5 Aug 20
8-K
Arrowhead Pharmaceuticals Reports Fiscal 2020 Second Quarter Results
7 May 20
8-K
Departure of Directors or Certain Officers
1 May 20
8-K
Entry into a Material Definitive Agreement
19 Mar 20
Registration and prospectus
S-8
Registration of securities for employees
18 May 21
424B5
Prospectus supplement for primary offering
5 Aug 20
S-8
Registration of securities for employees
22 May 20
424B5
Prospectus supplement for primary offering
4 Dec 19
424B5
Prospectus supplement for primary offering
2 Dec 19
S-3ASR
Automatic shelf registration
2 Dec 19
S-8
Registration of securities for employees
29 Mar 19
S-3ASR
Automatic shelf registration
29 Nov 18
S-8
Registration of securities for employees
21 Mar 18
424B5
Prospectus supplement for primary offering
18 Jan 18
Proxies
DEF 14A
Definitive proxy
27 Jan 21
DEF 14A
Definitive proxy
28 Jan 20
PRE 14A
Preliminary proxy
14 Jan 20
DEFA14A
Additional proxy soliciting materials
25 Jan 19
DEF 14A
Definitive proxy
25 Jan 19
DEF 14A
Definitive proxy
24 Jan 18
DEFA14A
Additional proxy soliciting materials
24 Jan 18
DEF 14A
Definitive proxy
31 Jan 17
DEFA14A
Additional proxy soliciting materials
31 Jan 17
DEF 14A
Definitive proxy
18 Jan 16
Other
UPLOAD
Letter from SEC
7 Mar 21
CORRESP
Correspondence with SEC
4 Feb 21
UPLOAD
Letter from SEC
26 Jan 21
CT ORDER
Confidential treatment order
18 Mar 19
EFFECT
Notice of effectiveness
2 Feb 17
EFFECT
Notice of effectiveness
2 Feb 17
CORRESP
Correspondence with SEC
31 Jan 17
CORRESP
Correspondence with SEC
31 Jan 17
CORRESP
Correspondence with SEC
18 Jan 17
CORRESP
Correspondence with SEC
18 Jan 17
Ownership
4
ARROWHEAD PHARMACEUTICALS / DOUGLAS B GIVEN ownership change
24 Feb 21
4
ARROWHEAD PHARMACEUTICALS / Patrick O'Brien ownership change
10 Feb 21
SC 13G/A
ARROWHEAD PHARMACEUTICALS / VANGUARD ownership change
10 Feb 21
SC 13G/A
ARROWHEAD PHARMACEUTICALS / BlackRock ownership change
26 Jan 21
4
ARROWHEAD PHARMACEUTICALS / DOUGLAS B GIVEN ownership change
19 Jan 21
4
ARROWHEAD PHARMACEUTICALS / James C Hamilton ownership change
15 Jan 21
4
ARROWHEAD PHARMACEUTICALS / Kenneth Allen Myszkowski ownership change
12 Jan 21
4
ARROWHEAD PHARMACEUTICALS / James Hassard ownership change
8 Jan 21
4
ARROWHEAD PHARMACEUTICALS / Patrick O'Brien ownership change
7 Jan 21
4
ARROWHEAD PHARMACEUTICALS / Kenneth Allen Myszkowski ownership change
7 Jan 21
Patents
GRANT
Utility
RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use
4 May 21
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit Angiopoietin-like 3 (also called ANGPTL3, ANGPL3, angiopoietin-like protein 3) gene expression, and compositions that include ANGPTL3 RNAi agents.
APP
Utility
Rnai Agents for Hepatitis B Virus Infection
8 Apr 21
Described are compositions and methods for inhibition of Hepatitis B virus gene expression.
APP
Utility
Integrin Targeting Ligands and Uses Thereof
1 Apr 21
Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described.
APP
Utility
Integrin Targeting Ligands and Uses Thereof
11 Mar 21
Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described.
APP
Utility
Rnai Therapy for Hepatitis B Virus Infection
25 Feb 21
Described are compositions and methods for inhibition of Hepatitis B virus gene expression.
Transcripts
2021 Q2
Earnings call transcript
5 May 21
2021 Q1
Earnings call transcript
5 Feb 21
2020 Q4
Earnings call transcript
23 Nov 20
2020 Q3
Earnings call transcript
5 Aug 20
2020 Q2
Earnings call transcript
8 May 20
2020 Q1
Earnings call transcript
5 Feb 20
2019 Q4
Earnings call transcript
26 Nov 19
2019 Q3
Earnings call transcript
5 Aug 19
2019 Q2
Earnings call transcript
8 May 19
2019 Q1
Earnings call transcript
8 Feb 19
Reddit threads
DD: Healthcare - BioNTech ($BNTX): Growth or Value?
27 May 21
$ATOS MEGATHREAD 5.18.21
18 May 21
Daily Discussion Thread - May 4th, 2021
4 May 21
Daily Discussion Thread - May 3rd, 2021
3 May 21
ARKX will be listed on Tuesday, March 30 2021
28 Mar 21
$PLTR Alex Karp Interview: FULL BREAKDOWN 3/16
16 Mar 21
Lengthy DD on $PHIO: 200% upside and short squeeze candidate
10 Mar 21
Any promising pharma stock in a mid-long term horizon?
3 Mar 21
To all ARKG holders out there
3 Mar 21
Good examples of former penny stocks that are consistently at $20+ today?
22 Feb 21